NRIXHealthcare · BiotechnologyThe 14 Wall Street analysts covering Nurix Therapeutics, Inc. hold a median 12-month price target of $35 — +116.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Nurix Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NRIX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +116.3% from it.
Of the 20 most recent actions, 8 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $34 → $36 |
| 13 Oct 2026 | Baird | Maintains | Outperform | $33 → $36 |
| 13 Oct 2026 | Needham | Reiterates | Buy | $34 |
| 13 Oct 2026 | Oppenheimer | Maintains | Outperform | $28 → $32 |
| 13 Oct 2026 | RBC Capital | Maintains | Outperform | $36 → $35 |
| 13 Oct 2026 | Truist Securities | Maintains | Buy | $34 → $33 |
| 10 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 10 Aug 2026 | RBC Capital | Maintains | Outperform | $33 → $36 |
| 4 Aug 2026 | Needham | Reiterates | Buy | $34 |
| 4 Aug 2026 | Needham | Reiterates | Buy | — |
| 28 July 2026 | Morgan Stanley | Maintains | Overweight | $36 → $38 |
| 28 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 22 July 2026 | UBS | Maintains | Buy | — |
| 22 July 2026 | UBS | Maintains | Buy | $23 → $31 |
| 13 July 2026 | Mizuho | Maintains | Outperform | — |
| 13 July 2026 | Mizuho | Maintains | Outperform | $30 → $34 |
| 10 July 2026 | BTIG | Reiterates | Buy | $32 |
| 10 July 2026 | BTIG | Reiterates | Buy | — |
| 10 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 July 2026 | HC Wainwright & Co. | Maintains | Buy | $32 → $34 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NRIX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Nurix Therapeutics, Inc. returned +30.1% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 56% of US stocks
Cheaper than 29% of US stocks
Cheaper than 31% of US stocks
Cheaper than 50% of US stocks
Higher than 99% of US stocks
Higher than 5% of US stocks
Higher than 99% of US stocks
Higher than 94% of US stocks
Higher than 92% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nurix Therapeutics, Inc. has a market value of $2.8B and an enterprise value of $1.8B.
Revenue in the twelve months to 31 May 2026: $36.8M. The latest quarter grew 8426.3% year on year.
Net income over the same four quarters: −$341.4M, a −928.4% net margin.
Diluted earnings per share, trailing twelve months: $−3.45.
Free cash flow in the twelve months to 31 May 2026: −$304.5M, after $10.8M of capital spending.
Trailing P/E: 10.6×; forward P/E: −20.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Nurix Therapeutics, Inc. employs 317 people — $116K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nurix Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Nurix Therapeutics announced that Sanofi has decided to discontinue the Phase 1 first-in-human trial of the oral STAT6 degrader SAR448272 and terminate the program.
Why it matters — NRIX watchers may wish to note the discontinuation of this clinical-stage program.
Seeking Alpha reports that Nurix initiated the phase 3 DAYBreak CLL-306 study to evaluate bexobrutideg against JAYPIRCA in relapsed/refractory CLL/SLL. The article cites phase 1/2 data and ongoing pivotal trials as supporting potential Accelerated Approval in third-line-or-later disease.
Why it matters — The study and potential approval pathway represent key clinical development milestones for Nurix’s bexobrutideg program in CLL/SLL.
Nurix Therapeutics reported quarterly earnings of $4.73 per share, above the Zacks Consensus Estimate of a $0.56-per-share loss. This compares with a loss of $1.03 per share a year earlier.
Why it matters — NRIX watchers may note the reported earnings exceeded the consensus estimate and improved from the year-ago result.
Nurix Therapeutics reported third-quarter 2026 financial results and a corporate update, including dosing the first patient in the registrational Phase 3 DAYBreak CLL-306 trial. The trial compares bexobrutideg with pirtobrutinib in relapsed or refractory CLL/SLL.
Why it matters — The first patient dose marks the start of the registrational Phase 3 trial, a development relevant to Nurix’s clinical program in CLL/SLL.
Nurix Therapeutics announced enrollment of the first patient in the Phase 1b/2 NX-5948-203 study of bexobrutideg combined with venetoclax for CLL/SLL. The initial cohort will focus on relapsed/refractory disease, with potential expansion to first-line CLL.
Why it matters — The enrollment marks the start of clinical evaluation of this combination, including a strategy to assess bexobrutideg with venetoclax and selected Roche-portfolio antibodies.
The 14 Wall Street analysts covering Nurix Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $25 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Nurix Therapeutics, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nurix Therapeutics, Inc. 91 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Nurix Therapeutics, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +116.3% from the last close, and Ticker Nerd's factor model ranks Nurix Therapeutics, Inc. 91 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nurix Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $45 over the next 12 months.
Nurix Therapeutics, Inc. returned +30.1% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted protein degradation medicines.
The most recent item we track (GlobeNewsWire, 3 Nov 2026): "Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272". Nurix Therapeutics announced that Sanofi has decided to discontinue the Phase 1 first-in-human trial of the oral STAT6 degrader SAR448272 and terminate the program.
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted protein degradation medicines. Nurix Therapeutics develops small-molecule and antibody-based therapies designed to modulate cellular protein levels through the ubiquitin-proteasome system, with applications in oncology, immunology, and inflammatory diseases. Its current pipeline includes investigational programs aimed at B-cell malignancies, immune-mediated disorders, and other serious conditions, supported by its DELigase discovery platform and expertise in E3 ligases. The company also advances partnered research and development programs with major pharmaceutical collaborators, combining internal drug discovery capabilities with broader development and commercialization efforts. Headquartered in San Francisco, California, Nurix Therapeutics plays a specialized role in the biotechnology market by translating protein degradation science into potential therapeutic candidates for diseases with limited treatment options.
CEO Dr. Arthur T. Sands M.D., Ph.D. · 317 employees · United States · https://www.nurixtx.com
